Ken Griffin Atai Life Sciences N.V. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.16 - $1.64 $56,955 - $80,524	49,100 Added 533.7%	58,300 $67,000
Q2 2024 Aug 14, 2024	SELL	$1.27 - $2.6 $86,614 - $177,320	-68,200 Reduced 88.11%	9,200 $12,000
Q1 2024 May 15, 2024	BUY	$1.5 - $2.19 $73,050 - $106,653	48,700 Added 169.69%	77,400 $152,000
Q4 2023 Feb 14, 2024	SELL	$1.04 - $1.55 $5,616 - $8,370	-5,400 Reduced 15.84%	28,700 $40,000
Q3 2023 Nov 14, 2023	BUY	$1.27 - $2.28 $35,941 - $64,523	28,300 Added 487.93%	34,100 $43,000
Q2 2023 Aug 14, 2023	SELL	$1.44 - $2.19 $7,776 - $11,826	-5,400 Reduced 48.21%	5,800 $9,000
Q1 2023 May 15, 2023	SELL	$1.17 - $2.7 $66,339 - $153,090	-56,700 Reduced 83.51%	11,200 $20,000
Q4 2022 Feb 14, 2023	BUY	$2.38 - $3.55 $73,780 - $110,050	31,000 Added 84.01%	67,900 $180,000
Q3 2022 Nov 14, 2022	SELL	$3.14 - $4.87 $2,198 - $3,409	-700 Reduced 1.86%	36,900 $122,000

12.4M

77.8K

50.3K

Ticker ATAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 165,875,008
Market Cap $197M
Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.